Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$7.70 USD

7.70
226,989

+0.10 (1.32%)

Updated Sep 19, 2024 04:00 PM ET

After-Market: $7.70 0.00 (0.00%) 7:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

New Strong Buy Stocks for September 13th

ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.

New Strong Buy Stocks for September 9th

DEC, AFRM, CRNC, ANGO and GIII have been added to the Zacks Rank #1 (Strong Buy) List on September 9, 2024.

AngioDynamics Stock Falls Despite CE Mark for Auryon System

ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.

AngioDynamics (ANGO) Upgraded to Strong Buy: Here's Why

AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AngioDynamics (ANGO) Down 3.1% Since Last Earnings Report: Can It Rebound?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US

Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.

Does AngioDynamics (ANGO) Have the Potential to Rally 77.03% as Wall Street Analysts Expect?

The mean of analysts' price targets for AngioDynamics (ANGO) points to a 77% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Boston Scientific (BSX) Rides on Global Growth, Buyouts

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Wall Street Analysts Predict a 74.25% Upside in AngioDynamics (ANGO): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 74.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

New Strong Buy Stocks for July 29th

KRO, FUNC, PRG, ANGO and HGTY have been added to the Zacks Rank #1 (Strong Buy) List on July 29, 2024.

AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down

AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.

AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 70% and 0.18%, respectively, for the quarter ended May 2024. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval

AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.

AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment

AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

AngioDynamics (ANGO) Settles Patent Litigations With BD

AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.

Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors

In the most recent trading session, AngioDynamics (ANGO) closed at $5.37, indicating a -0.74% shift from the previous trading day.

Why AngioDynamics (ANGO) Dipped More Than Broader Market Today

In the most recent trading session, AngioDynamics (ANGO) closed at $5.67, indicating a -1.39% shift from the previous trading day.

AngioDynamics (ANGO) Gains But Lags Market: What You Should Know

AngioDynamics (ANGO) closed the most recent trading day at $5.50, moving +0.18% from the previous trading session.

Here's Why AngioDynamics (ANGO) Gained But Lagged the Market Today

In the most recent trading session, AngioDynamics (ANGO) closed at $5.99, indicating a +1.7% shift from the previous trading day.

AngioDynamics (ANGO) Divests Its PICC & Midline Businesses

AngioDynamics (ANGO) finalizes its PICC and Midline businesses divestment to Spectrum Vascular to optimize its product portfolio and to focus on strengthening its med tech segment.

Why AngioDynamics (ANGO) Outpaced the Stock Market Today

AngioDynamics (ANGO) closed at $6.17 in the latest trading session, marking a +1.31% move from the prior day.

AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why

The latest trading day saw AngioDynamics (ANGO) settling at $6.09, representing a -0.98% change from its previous close.